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Abstract 
Purpose: Definitive radiation therapy is the mainstay of treatment for early stage laryngeal squamous cell carcinoma 
(LSCC). However, up to 30% of the patients do not respond to radiotherapy. Unfortunately, we are unable to predict 
which tumors are likely to respond to radiation, and which will be resistant and persist. Therefore, the development 
of novel markers to predict response to radiotherapy is urgently needed. This study was designed to evaluate the 
expression pattern of microRNAs (miRNAs) in LSCC in order to identify markers capable of segregating radioresist‑
ant and radiosensitive tumors and to investigate the relationship between the expression of these miRNAs and the 
prognosis of LSCC.
Methods: The expression profile of 667 miRNAs was determined in an initial screening of nine early‑stage LSCC sam‑
ples (5 radioresistant and 4 radiosensitive) using TaqMan Low‑Density Array (TLDA). Real‑time polymerase chain reac‑
tions were performed to validate the expression of selected miRNAs in an expanded LSCC cohort (20 radioresistant 
and 14 radiosensitive). The miRNA expression level was scored as high or low based on the median of the expression 
in the LSCC samples.
Results: A comprehensive miRNA expression profiling enabled the identification of four miRNAs (miR‑296‑5p miR‑
452, miR‑183* and miR‑200c) differentially expressed in radioresistant LSCC. Moreover, the analysis of additional 34 
LSCC samples, confirmed the expression of miR‑296‑5p as significantly related to radioresistance (p = 0.002) as well as 
an association of this marker with recurrence (p = 0.025) in early stage laryngeal cancer.
Conclusions: This study indicates that miR‑296‑5p expression is associated with resistance to radiotherapy and 
tumor recurrence in early stage LSCC, showing the feasibility of this marker as a novel prognostic factor for this malig‑
nance. Furthermore, miR‑296‑5p expression could be helpful in the identification of tumors resistant to radiotherapy; 
thus aiding the clinicians in the choice of the best therapeutic scheme to be used in each case.
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Background
Laryngeal cancer represents the second most com-
mon site of head and neck tumors [1, 2], and has squa-
mous cell carcinoma as the most important histology 
[2]. Accounting for approximately 160,000 new cases per 
year and for 2.5% of all tumors in males, LSCC remains 
a major disease burden worldwide. Treatment options 
comprise surgery, radiotherapy, chemotherapy or a com-
bination of modalities [3, 4]. Despite refinement of mul-
timodal therapies, the 5-year relative survival percentage 
has been stable at around 60 for the last decades for early 
laryngeal cancer [5].
Definitive radiation therapy is the mainstay of treat-
ment for early stage (T1-T2 N0) laryngeal squamous cell 
carcinoma (LSCC). However, 6–15% of patients with 
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stage 1 disease and 20–31% of patients with stage 2 dis-
ease do not respond to radiotherapy [6]. If a patient fails 
radiotherapy, surgery is the main treatment option that 
may offer a cure, and up to 50% will require a total lar-
yngectomy as salvage treatment. Moreover, when used 
as salvage surgery after a failed radiotherapy course, 
laryngectomy presents an increased complication rate 
[7]. Remarkably, for these failed cases, definitive can-
cer cure is delayed by the course of radiotherapy with a 
risk of tumor progression, adversely affecting patient 
prognosis still further. Unfortunately, we are unable to 
predict which tumors are likely to respond to radiation, 
and those, which will be resistant and persist. Therefore, 
it would be desirable to find novel and valuable markers 
to predict beforehand which patients will benefit from 
radiotherapy.
Relevant clinical factors associated with local recur-
rence after radiotherapy are tumor size, tumor stage, 
overall treatment time and radiotherapy fraction size 
[8–10]. Treatment choice is now mainly based on T-stage 
[11], however, this is insufficient to warrant recurrence-
free survival as observed in heterogeneous responses and 
survival rates presented by LSCC patients [6].
Molecular markers have the potential to help in the 
selection of treatment through response prediction and 
determination of cancer prognosis [12, 13] Previous stud-
ies have identified few molecular markers, such as p53, 
cyclin D1, EGFR, VEGF, IGF1R, COX2 and Ki67, asso-
ciated with local relapse and overall survival in early 
laryngeal carcinoma [12, 14–16]. However, some of these 
findings are conflicting and none of these markers are 
being used in clinical practice.
MicroRNAs (miRNAs) are non-coding RNAs with 
18–25 nucleotides, described as negative regulators of 
gene expression in a variety of multicellular organisms. 
These small molecules harbor the capacity to bind and 
silence specific messenger RNA (mRNA) targets, induc-
ing their degradation, or inhibiting their translation [17]. 
MicroRNAs play important roles in various biological 
processes, such as apoptosis, cell proliferation, cell dif-
ferentiation, tumorigenesis, and multidrug resistance 
(MDR) [18]. Emerging evidences revealed that miRNA 
expression patterns are significantly changed in cancer 
cells submitted to ionizing radiation [19]. Many studies 
have shown modulation of radiosensitivity by altering 
miRNA levels in various malignances, such as lung can-
cer cells in vitro [20] and breast cancer cells in vivo [21].
The purposes of this study were to assess the global 
miRNA expression profile of patients with T1–T2 N0 
laryngeal cancer treated with primary radiation therapy, 
in order to identify miRNAs able to segregate radioresist-
ant and radiosensitive tumors, thus serving as markers 
to predict radiotherapy resistance. Moreover, the role of 
miRNAs in prognosis will be assessed by searching for 
associations between the expression of selected miR-




This retrospective study included 34 patients with pri-
mary LSCC tumors (glottic and supraglottic) treated with 
radiotherapy as first and single modality treatment with 
curative intent at the Barretos Cancer Hospital, Barretos, 
São Paulo, Brazil, between 2000 and 2010. Diagnosis of 
LSCC was determined according to the WHO criteria.
Patients were identified as harboring radioresistant or 
radiosensitive tumors depending upon their response to 
radiotherapy. Tumors were staged according to the TNM 
classification [22] with all cases being clinically T1–T2, 
clinically nodal negative (N0) and negative for distant 
metastases (M0) at the time of treatment.
The radioresistant cohort consisted of 20 LSCC 
patients. The criteria for radioresistant tumors were: (a) 
radiotherapy had to be given as a single modality treat-
ment with curative intent for a biopsy-proven squamous 
cell carcinoma of the larynx; (b) biopsy-proven recurrent 
squamous cell carcinoma, with the recurrence occurring 
at the local or locoregional original anatomical site after 
finishing the course of radiotherapy.
The radiosensitive cohort of tumors was comprised of 
14 LSCC patients. The criteria for radiosensitive tumors 
were: (a) radiotherapy had to be given as a single modal-
ity treatment with curative intent for a biopsy-proven 
squamous cell carcinoma of the larynx; (b) post treat-
ment, patients had a minimum follow-up of 3 years with 
no evidence of a recurrent laryngeal tumor. The defini-
tion for LSCC recurrence adopted in this study is the 
presence of tumor cell in the same site of the primary 
tumor or radiological evidence of locoregional disease 
after finishing the course of radiotherapy and during the 
first 3 years of follow-up.
This study was approved by the local IRB for the use 
of archival biopsy material and patient clinical data col-
lection. Medical records of patients were reviewed for 
standard demographic data, pretreatment classification, 
tumor staging, radiation therapy parameters, and disease 
outcome.
Radiotherapy
Radiation treatment parameters were as follows: bilateral 
laryngeal opposed wedged fields using beam energies 
of 6 MV, 5 fractions per week, without planned treat-
ment breaks. Patients were treated with daily fractions of 
2–2.25 Gy to a total median dose of 66 Gy (range 49.5–
79 Gy) over 47 days (range 38–79 days).
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RNA isolation and cDNA synthesis
Biopsies sections (5-μm thick) were performed from pre-
treatment archival tissue blocks of the radioresistant and 
radiosensitive tumors. Total RNA was isolated using the 
miRNeasy FFPE Kit (Qiagen, Hilden, Germany), accord-
ing to the manufacturer’s instructions. Ten nanograms of 
total RNA from each sample were subjected to reverse 
transcription using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, 
USA) and specific stem-loop primers for each of the 
microRNAs selected, in accordance with the manufac-
turer’s recommendations.
Global microRNA profiling
Global microRNA expression profiling of FFPE sam-
ples in a discovering set comprised of 9 patients (5 from 
the radioresistant group and 4 from the radiosensitive 
group) was performed using the TaqMan Human Micro-
RNA Cards Set v2.0 (Applied Biosystems), allowing the 
evaluation of the expression level of 667 human micro-
RNAs. Forty nanograms of total RNA from each sample 
was reverse transcribed into cDNA using the TaqMan 
miRNA Reverse Transcription Kit (Applied Biosystems) 
and Megaplex RT Primers (Applied Biosystems). Next, 
the product obtained from the RT reactions was pre-
amplified using the TaqMan PreAmp Master Mix Kit 
(Applied Biosystems) and Megaplex PreAmp Primers 
(Applied Biosystems). The amplified-cDNA was then 
transferred to the TaqMan Human MicroRNA Cards 
Set v2.0 and the amplification was carried out in the 
7900HT Real-Time PCR System (Applied Biosystems). 
The data obtained was analyzed using the software Data-
Assist v3.0 (Applied Biosystems). The fold-change dif-
ference between radioresistant and radiosensitive cases 
was calculated using the 2−ΔΔCt method [23]. The small 
nuclear RNA U6 was used as endogenous control and 
the radiosensitive cases were assigned as reference. Cases 
were scored as differentially expressed if a 4-fold-change 
increase was observed.
Validation of the differentially expressed microRNAs
The expression level of the miRNAs selected for the vali-
dation step was evaluated in a total of 34 samples (20 
radioresistant and 14 radiosensitive) using individual 
TaqMan MicroRNA Assays (Applied Biosystems). Each 
assay was conducted using the TaqMan MicroRNA 
Reverse Transcription kit (Applied Biosystems) accord-
ing to the manufacturer’s protocols. Briefly, 10  ng of 
total RNA were reverse-transcribed using MultiScribe 
Reverse Transcriptase (Applied Biosystems) and a stem-
loop primer (Applied Biosystems). The mixture was incu-
bated at 16°C for 30 min, 42°C for 30 min and 85°C for 
5 min. Quantitative RT-PCR (qRT-PCR) was performed 
using TaqMan PCR kit (Applied Biosystems) on a 7500 
Fast Real-Time PCR System (Applied Biosystems). Three 
technical replicates of each sample were performed for 
every microRNA. To evaluate the differential expression 
of each microRNA between radioresistant and radio-
sensitive cases, the 2−ΔΔCt method was employed [23]. 
Mean Ct values of U6 small nuclear RNA was used for 
normalization.
Statistical analysis
To search for differentially expressed microRNAs 
between both groups in the global miRNA expres-
sion profiling, ΔCt values from each microRNA were 
evaluated using the t-Student test with the Benjamini–
Hochberg adjustment for false discovery rate (FDR) as 
implemented in the DataAssist software v3.0 (Applied 
Biosystems). The individual assay results were analyzed 
after normalization of data. ΔCT values of microRNAs 
assayed in the validation step using individual TaqMan 
assays were used for comparisons between groups using 
Mann–Whitney U test for non-normal distribution.
The miRNA levels measured during the validation step 
were converted into discrete variables by splitting the 
samples into two classes (high and low expression) using 
the ΔCt median level considering all samples evalu-
ated as cutoff. The Chi square test and Fisher’s exact test 
were used to evaluate the associations between miRNA 
expression and clinical variables, as appropriate. The 
Kaplan–Meier method was used to estimate disease-free 
survival (DFS) of patients, and the log-rank test was used 
to examine the differences between groups. The DFS was 
defined as the time interval between the date of the end 
of the radiation therapy and the date of diagnosis of the 
first recurrence, or last date of follow-up if recurrence was 
not observed. A p value of <0.05 indicated the presence of 
statistically significant difference between groups. All sta-
tistical analyses were performed using SPSS statistics 20.0.
Results
Characteristics of the patients
The clinical and histological characteristics of the 34 
patients enrolled in this study are listed in Table  1. 
Patients were mainly male (88.2%), with age ranging from 
39 to 85 years (median 62.5 years). Tobacco use (current 
or former) was reported by 91.2% of the patients. Pri-
mary tumor sites were predominantly glottic (79.4%) and 
tumor stage at diagnosis was T1 in 47.1% and T2 in 52.9% 
of the cases. Most patients (70.6%) received at least 70 Gy 
in a range from 6,300 to 7,020  cGy (total median dose, 
66 Gy), within a median delivery interval of treatment of 
55 days (range 38–79 days). None of the clinical and ther-
apeutic variables were correlated with the radioresistant 
tumors, as noted in Table 1.
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MicroRNA expression in LSCC samples
Comprehensive miRNA profiles were generated from 
LSCC samples collected from radioresistant (n = 5) and 
radiosensitive (n =  4) patients using a quantitative RT-
PCR array platform (Additional file 1: Table S1). miRNAs 
were considered differentially expressed in concordance 
with two criteria: (1) miRNAs with FDR-adjusted p value 
<0.3, as previously suggested [24], and (2) an increase in 
the expression level of the radioresistant group in com-
parison to the radiosensitive group greater than 4-fold. 
Thus, by using a FDR-adjusted p value <0.3, 42 miRNAs 
could be considered as differentially expressed between 
radioresistant and radiosensitive samples considering 
a 4-fold difference. From those, based in the expression 
level and literature searching, 15 miRNA were selected 
for further analysis. All miRNAs that were at least 2-fold 
up-regulated or down-regulated are presented in Table 2.
Due to the scarcity of RNA quantity in many samples, 
it would be impossible to evaluate all 15 differentially 
expressed miRNAs selected in all samples. After a deep 
review of the available literature data from the 15 miR-
NAs identified in the discovery series, miR-452, miR-
200c, miR-183* and miR-296-5p were selected for further 
analyses. The expression levels of these four selected 
miRNAs were determined in the entire cohort of samples 
(20 radioresistant and 14 radiosensitive) and, by using the 
median value as threshold cutoff, the miRNA expression 
was scored as low level, below the median value, and high 
level, above the median value (Additional file 2: Table S2).
miR‑296‑5p expression is associated with patient 
prognosis
The expression levels (high or low) of miR-452, miR-
200c, miR-183* and miR-296-5p were analyzed for poten-
tial correlations with clinical characteristics of the LSCC 
patients, including age, gender, tobacco consumption, 
tumor site, tumor stage, and radiosensitivity. The high 
expression of miR-296-5p showed a significant correla-
tion with resistance to radiotherapy (p = 0.010; Table 3). 
No associations were observed between the clinical fea-
tures and expression status of the other miRNAs tested.
The comparison of the expression of miR-296-5p 
between the radioresistant and radiosensitive groups 
reveals a significant higher expression of this miRNA in 
the radioresistant group (p  =  0.002, Fig.  1). Expression 
of miR-452, miR-200c and miR-183* between the radi-
oresistant and radiosensitive groups were not significant 
associated with radioresistance (Fig. 1).
The 3-year disease-free survival (DFS) rate consider-
ing all patients included in the study was 34% (Fig.  2a). 
Additionally, we investigated the association between 
the expression levels of the four selected miRNAs and 
the 3-year DFS. According to this analysis, 41.6% of the 
patients with low expression of miR-296-5p presented 
recurrences, while relapses were detected in 82.4% of 
the LSCC patients with high expression of this miRNA, 
and this difference was statistically significant (p = 0.025, 
OR =  8.6, 95 CI 1.7–42.2, Fig.  2b). Expression levels of 
miR-452, miR-200c and miR-183* were not associated 
with disease-free survival in this cohort (data not shown).
Discussion
Despite recent advances in the multidisciplinary manage-
ment of early stage laryngeal cancer, including surgical 
resection or larynx-preservation protocols, a substantial 
proportion of patients with localized or locally advanced 
disease will eventually relapse and die [25]. Radiotherapy 
as the initial treatment is commonly used, offering a pos-
sibility to preserve laryngeal function and reserving sur-
gery as a salvage procedure. Nodal involvement, gender, 
tumor volume, impaired vocal cord mobility, tumor inva-
sion of cartilage, and overall treatment time are factors 
found to be of prognostic importance. However, these 
prognostic factors fail to differentiate patients with good 
outcome of radiotherapy from those patients that will 









n (%) n (%)
Gender
 Male 30 (88.2) 12 (40.0) 18 (60.0) 1.0
 Female 4 (11.8) 2 (50.0) 2 (50.0)
Age
 ≤60 years 16 (47.1) 5 (31.2) 11 (68.8) 0.51
 >60 years 18 (52.9) 9 (50.0) 9 (50.0)
Tobacco consumption
 Yes 31 (91.2) 14 (45.2) 17 (54.8) 0.25
 No 3 (8.8) 0 (0) 3 (100.0)
Tumor site
 Supraglottic 7 (20.6) 2 (28.6) 5 (71.4) 1.0
 Glottic 27 (79.4) 12 (44.4) 15 (55.6)
Tumor stage
 I 16 (47.1) 8 (50) 8 (50) 0.49
 II 18 (52.9) 6 (33.3) 12 (66.7)
Radiotherapy dose
 <70 Gy 10 (29.4) 5 (50.0) 5 (50.0) 0.7
 ≥70 Gy 24 (70.6) 9 (37.5) 15 (62.5)
Treatment time
 ≤55 days 20 (58.8) 9 (45.0) 11 (55.0) 0.72
 >55 days 14 (41.2) 5 (37.5) 9 (64.3)
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Table 2 A list of miRNAs differentially expressed according to the TaqMan Human MicroRNA Array
Up‑regulated Down‑regulated
microRNA Fold‑change FDR‑adjusted p‑value microRNA Fold‑change FDR‑adjusted p value
hsa‑miR‑642 2.02 0.3869 hsa‑miR‑106b 2.01 0.2162
hsa‑miR‑744 2.02 0.4254 hsa‑miR‑302b 2.05 0.5657
hsa‑miR‑221 2.03 0.3475 hsa‑miR‑136* 2.06 0.5306
hsa‑miR‑193b* 2.07 0.3359 hsa‑miR‑127‑5p 2.09 0.5626
hsa‑miR‑193b 2.08 0.4149 hsa‑miR‑152 2.09 0.3678
hsa‑miR‑18b 2.11 0.3012 hsa‑miR‑34c‑5p 2.09 0.4936
hsa‑miR‑222*‑ 2.15 0.4874 hsa‑miR‑199a‑5p 2.11 0.6033
hsa‑miR‑944 2.16 0.4246 hsa‑miR‑190b 2.12 0.6416
hsa‑miR‑766‑ 2.21 0.3723 hsa‑miR‑140‑3p 2.14 0.4081
hsa‑miR‑106b* 2.22 0.3155 hsa‑let‑7i* 2.16 0.5682
hsa‑miR‑942 2.35 0.3275 hsa‑miR‑195 2.17 0.508
hsa‑miR‑135a 2.41 0.1506 hsa‑miR‑302c 2.17 0.5853
hsa‑miR‑652 2.41 0.2572 hsa‑miR‑488 2.17 0.5469
hsa‑miR‑124 2.42 0.3872 hsa‑miR‑411* 2.17 0.5271
hsa‑miR‑105 2.51 0.2277 hsa‑miR‑21 2.18 0.3333
hsa‑miR‑923 2.62 0.5362 hsa‑miR‑590‑5p 2.18 0.37
hsa‑miR‑138 2.71 0.2162 hsa‑miR‑29c 2.23 0.4804
hsa‑miR‑181a‑2* 2.78 0.2034 hsa‑miR‑454 2.24 0.3152
hsa‑miR‑23b 2.84 0.2235 hsa‑miR‑10b* 2.25 0.5091
hsa‑miR‑224 2.85 0.2626 hsa‑miR‑378* 2.29 0.4961
hsa‑miR‑141 2.89 0.3926 hsa‑miR‑380* 2.31 0.4251
hsa‑miR‑205 3.13 0.2706 hsa‑miR‑661 2.31 0.5051
hsa‑miR‑129‑3p 3.53 0.1788 hsa‑miR‑10a 2.34 0.1452
hsa‑miR‑188‑5p 3.58 0.5457 hsa‑miR‑148b* 2.34 0.4926
hsa‑miR‑107 3.81 0.1843 hsa‑miR‑592 2.35 0.4694
hsa‑miR‑183 3.91 0.1201 hsa‑miR‑449b 2.36 0.526
hsa-miR-296-5p 4.26 0.084 hsa‑miR‑487a 2.36 0.511
hsa-miR-23a 4.58 0.1771 hsa‑miR‑199a‑3p 2.37 0.4496
hsa-miR-22 4.78 0.3268 hsa‑miR‑181a 2.41 0.3499
hsa-miR-801 5.87 0.127 hsa‑miR‑30a* 2.48 0.3854
hsa-miR-200a 6.22 0.3678 hsa‑miR‑144* 2.51 0.5976
hsa-miR-203 6.22 0.1755 hsa‑miR‑509‑3p 2.56 0.4307
hsa-miR-429 6.68 0.1588 hsa‑miR‑146b‑5p 2.57 0.224
hsa-miR-183* 7.84 0.0203 hsa‑miR‑154* 2.57 0.3571
hsa-miR-200b* 8.02 0.1744 hsa‑miR‑638 2.61 0.4688
hsa-miR-601 8.31 0.2335 hsa‑miR‑328 2.61 0.3059
hsa-miR-200b 9.41 0.1332 hsa‑miR‑656 2.62 0.4201
hsa-miR-200c 9.77 0.1334 hsa‑miR‑146b‑3p 2.68 0.328
hsa-miR-200a* 9.86 0.0974 hsa‑miR‑202 2.77 0.3485
hsa-miR-452 17.94 0.0238 hsa‑miR‑548b‑5p 2.77 0.4288
hsa-miR-650 18.46 0.1454 hsa‑miR‑340 2.78 0.2592
hsa-miR-378 28.01 0.3958 hsa‑miR‑15a* 2.81 0.2874
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Table 2 continued
Up‑regulated Down‑regulated














































All miRNA listed here presented a FDR-adjusted p value <0.3. The 42 miRNAs selected as differentially expressed are marked in italics.
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not respond to the treatment. In spite of the high rates 
of response to radiotherapy, around 30% of patients with 
small, good prognosis tumors are not cured by this treat-
ment and must undergo salvage laryngectomy (partial or 
total). Therefore, an accurate and reproducible estima-
tion of prognosis in patients with early laryngeal cancer is 
important as an opportunity to spare patients from inef-
fective and toxic therapies.
To better understand the biology of radiation response, 
analysis of the phenotype of tumor cells has been under-
way for the last several years. Previous studies have eval-
uated the prognostic significance of various biomarkers 
including angiogenesis markers, members of the pro-
apoptotic family, cell cycle regulators, and proliferation 
markers in head and neck cancer [19, 20, 26–28]. How-
ever, results have been quite mixed, reflecting the mul-
titude of factors that contribute to the complex tumor 
biology as well as the heterogeneity of laryngeal cancers 
in terms of biology, site, stage, and prognosis [20].
Several studies have reported specific miRNA expres-
sion in different cancer cell types and in distinct dif-
ferentiation tumor stages [21, 29]. Some of them have 
exploited the potential of miRNAs as prognostic markers 
in HNSCC and found associations between the low levels 
of miRNAs such as miR-205 and let-7d and high levels of 
miR-451 with disease progression and increased risk for 
local and regional recurrence [30]. As diagnostic markers, 
the ratio between the expression of miR-221 and miR-375 
was able to discriminate HNSCC and normal samples 
with a specificity of 93% and a sensitivity of 92% [31]. 
Moreover, although a small number of cases was evalu-
ated, Fletcher et al. found a specific expression of miR-205 
in metastatic lymph nodes of HNSCC patients [32].
Specifically in laryngeal cancer, five miRNAs (miR-
331-3p, miR 603, miR, 1303, miR-660-5p and miR-
212-3p) were identified specifically in plasma samples 
from affected patients, while theis expression was absent 
in the normal population. Therefore, these findings sug-
gest miRNAs as promissor biomarkers for laryngeal can-
cer early diagnostic [33]. Cao et al. identified that miR-21, 
miR-93, miR-205, and miR-708 were upregulated and 
miR-125b and miR-145 were downregulated between 
adjacent normal tissue and laryngeal cancer, these results 
points to the importance of miRNAs in tumorigenesis 
and tumor progression of laryngeal cancer [34].
In turn, some studies have exploited the potential 
role of miRNAs in modulating radiosensitivity in dif-
ferent tumors. Given the fact that the local control of 
Table 3 Correlation between  the expression level of  microRNAs miR-296-5p, miR-452, miR-183* and  miR-200c and  the 
clinical and pathological characteristics of the LSCC patients enrolled in the study
Italic value indicates statistical significance at p < 0.05.
p (Fisher’s exact); NS (p > 0.05).
Variable Categories Number of cases miR‑296‑5p miR‑452 miR‑183* miR‑200c
Low High Low High Low High Low High
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age (years) ≤60 years 16 6 (35.3) 10 (58.8) 8 (47.1) 8 (47.1) 8 (47.1) 8 (47.1) 8 (50.0) 8 (47.1)
>60 years 18 11 (64.7) 7 (41.2) 9 (52.9) 9 (52.9) 9 (52.9) 9 (52.9) 8 (50.0) 9 (52.9)
p (2‑sided) NS NS NS NS
Gender Female 4 2 (11.8) 2 (11.8) 2 (11.8) 2 (11.8) 2 (11.8) 2 (11.8) 2 (12.5) 2 (12.5)
Male 30 15 (88.2) 15 (88.2) 15 (88.2) 15 (88.2) 15 (88.2) 15 (88.2) 14 (87.5) 15 (88.2)
p (2‑sided) NS NS NS NS
Smoking No 3 0 (0) 3 (17.6) 1 (5.9) 2 (11.8) 0 (0) 3 (17.6) 2 (12.5) 1 (9.1)
Yes 31 17 (100) 14 (82.4) 16 (94.1) 15 (88.2) 17 (100) 14 (82.4) 14 (87.5) 16 (94.1)
p (2‑sided) NS NS NS NS
Tumor site* Glottic 27 15 (88.2) 12 (70.6) 14 (82.4) 13 (76.5) 14 (82.4) 13 (76.5) 14 (87.5) 12 (70.6)
Supraglottic 7 2 (11.8) 5 (29.4) 3 1 (7.6) 4 (23.5) 3 (17.6) 4 (23.5) 2 (12.5) 5 (29.4)
p (2‑sided) NS NS NS NS
Tumor stage I 16 7 (41.2) 9 (52.9) 9 (52.9) 7 (41.2) 7 (41.2) 9 (52.9) 7 (43.8) 9 (52.9)
II 18 10 (58.8) 8 (47.1) 8 (47.1) 10 (58.8) 10 (58.8) 8 (47.1) 9 (56.2) 8 (47.1)
p (2‑sided) NS NS NS NS
Radiosensibility Sensivite 14 11 (64.7) 3 (17.6) 8 (47.1) 6 (35.3) 9 (52.9) 5 (29.4) 7 (43.8) 7 (41.2)
Resistant 20 6 (35.3) 14 (82.4) 9 (52.9) 11 (64.7) 8 (47.1) 12 (70.6) 9 (56.2) 10 (58.8)
p (2‑sided) 0.01 NS NS NS
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Fig. 1 Comparison between radioresistant and radiosensitive groups relative to expression level (Mann–Whitney test): a miR‑296‑5p, b miR‑183, c 
miR‑452, d miR‑200c.
Fig. 2 Survival curves for 34 laryngeal squamous cell carcinoma patients. a 3‑years disease‑free survival for all patients. b 3‑years disease‑free 
survival rate according to miR‑296‑5p expression level in LSCC samples.
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early-stage laryngeal cancers fails in one third of the 
patients treated with definitive radiotherapy, we sought 
to identify miRNA-based markers which expression pro-
file could discriminate between radiosensitive patients, 
who could actually benefit from this treatment approach, 
and radioresistant ones.
Cancer stem cells are known to play an important roll in 
radiation resistance and this important biological charac-
teristic may be mediated through miRNA regulation [35, 
36]. Huang et  al. conducted a study in which laryngeal 
cancer stem cells were successfully isolated and than irra-
diated. The miRNA expression analyzes were performed 
before and after radiation and 70 miRNA were found to 
be differentially expressed. This experiment in cell lines 
demonstrated that laryngeal stem cells have different 
behavior in response to radiation, so tumor radioresist-
ance observed in clinical practice may be intermediated 
by laryngeal stem cells through miRNA disorders [37]. 
The better understanding of miRNAs is essential for early 
interventions and better clinical results.
Of note, other studies have indicated miRNAs as 
important mediators of radioresistance in human tumors 
without focusing in stem cells, such as non-Hodgkin’s 
lymphoma, oral squamous cell carcinoma, esophageal 
and lung cancers. Wu et al. (2012) showed that miR-148b 
is able to enhance radiosensitivity of non-Hodgkin’s lym-
phoma cells by promoting radiation-induced apoptosis 
[38]. As such, the involvement of miRNAs in the radiation 
resistance of esophageal cancer cell was established by Su 
et al. [39]. Shiiba et al. demonstrated that down-regulated 
miR-125b expression was associated with radioresistance 
mechanisms in oral squamous cell carcinoma and they 
suggested that the control of the expression or activity of 
miR-125b might contribute to overcoming radioresist-
ance in this oral malignancy [40]. Oh et al. found overex-
pression of miR-let-7a in radiosensitive A549 lung cancer 
cells in a miRNA profile study [41], while Grosso et  al. 
showed that lung cancer cells expressing miR-210 exhibit 
a radioresistance similar to that found in hypoxic control 
cells [42]. According to this study, miR-210 stable expres-
sion mimics hypoxia-induced metabolic changes associ-
ated with a slight but significant stabilization of HIF-1α, 
and this information, combined with a strong reduction 
of radioresistance following HIF-1 silencing, reinforces 
the central role of HIF-1 in the resistance to radiotherapy. 
The molecular mechanism responsible for this radiore-
sistance is not fully understood and is likely mediated by 
a complex network of miR-210 targets involved in a wide 
set of biological functions, including cell cycle control, 
survival, DNA repair and cell metabolism.
Our study was the first to evaluate the miRNA expres-
sion profile of LSCC and found miR-296-5p up-regulated 
in radioresistant patients and this high expression sig-
nificantly correlates with tumor recurrence. The micro-
RNA miR-296-5p is involved in many physiological 
and pathologic processes, such as angiogenesis, insulin 
metabolism, tumorigenesis and fetal alcohol syndrome 
[43–45]. Using a miRNA microarray approach to ana-
lyze the miRNA expression profile in esophageal cancer, 
Hong et al. showed that miR-296-5p might mediate drug 
resistance at least in part through regulation of MDR1 
and apoptosis [46]. Furthermore, these authors also dem-
onstrated that esophageal tumors with high expression 
of miR-296-5p had a worse prognosis compared with 
those with low expression. Along the same line, our find-
ings also correlated the high expression of miR-296-5p 
with worse recurrence-free survival for early-stage LSCC 
patients.
The possibility of evaluating small fragments from 
early laryngeal carcinoma biopsies to predict the 
response to definitive radiotherapy is relevant given the 
difficulty of differentiating non-responder patients at 
high risk of relapse that should receive a more aggressive 
treatment, obviating potentially hazardous overtreat-
ment in the group with a presumed favorable outcome. 
Based in the results present here, we may speculate that 
the expression of miR-296-5p in biopsy of laryngeal can-
cers could be a helpful biomarker to identify subjects 
resistant to radiotherapy. It is worth mentioning that 
the present study has some limitations. Remarkably, the 
patient number was limited. Therefore, further valida-
tion of these results requires studies with larger patient 
groups, which will allow the determination of cutoff 
values to easily classify the miR-296-5p expression level 
as “high” or “low”. So, only after the establishment of 
these cutoffs and by achieving a good predictive nega-
tive value, this molecular approach could constitute a 
valuable tool to predict the radiotherapy response in a 
biopsy of the primary tumor, helping the clinicians in the 
adoption of the most effective treatment for early LSCC 
patients.
Conclusions
In the present study, the only one to our knowledge 
exploring the prognostic role of miRNAs in early laryn-
geal cancer in radiosensitive and radioresistant patients, 
we have shown that high expression level of miR-
296-5p is an adverse prognostic factor for recurrence 
in patients with early stage LSCC treated with defini-
tive radiotherapy. Moreover, the evaluation of the miR-
296-5p expression could help clinicians to discriminate 
among LSCC patients who will take benefit from radio-
therapy and who should take surgery as the first cura-
tive attempt.
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